Logo image of LGVN

LONGEVERON INC-A (LGVN) Stock Fundamental Analysis

NASDAQ:LGVN - Nasdaq - US54303L2034 - Common Stock - Currency: USD

1.75  +0.12 (+7.36%)

Fundamental Rating

4

Taking everything into account, LGVN scores 4 out of 10 in our fundamental rating. LGVN was compared to 568 industry peers in the Biotechnology industry. LGVN has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, LGVN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

LGVN had negative earnings in the past year.
LGVN had a negative operating cash flow in the past year.
In the past 5 years LGVN always reported negative net income.
LGVN had a negative operating cash flow in each of the past 5 years.
LGVN Yearly Net Income VS EBIT VS OCF VS FCFLGVN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

LGVN's Return On Assets of -96.33% is on the low side compared to the rest of the industry. LGVN is outperformed by 75.18% of its industry peers.
With a Return On Equity value of -112.49%, LGVN perfoms like the industry average, outperforming 42.78% of the companies in the same industry.
Industry RankSector Rank
ROA -96.33%
ROE -112.49%
ROIC N/A
ROA(3y)-116.31%
ROA(5y)-85.81%
ROE(3y)-177.95%
ROE(5y)-153.9%
ROIC(3y)N/A
ROIC(5y)N/A
LGVN Yearly ROA, ROE, ROICLGVN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

LGVN has a better Gross Margin (78.80%) than 84.15% of its industry peers.
In the last couple of years the Gross Margin of LGVN has grown nicely.
The Profit Margin and Operating Margin are not available for LGVN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 78.8%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.36%
GM growth 5Y20.42%
LGVN Yearly Profit, Operating, Gross MarginsLGVN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

7

2. Health

2.1 Basic Checks

LGVN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LGVN has more shares outstanding
LGVN has more shares outstanding than it did 5 years ago.
LGVN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LGVN Yearly Shares OutstandingLGVN Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 5M 10M
LGVN Yearly Total Debt VS Total AssetsLGVN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

LGVN has an Altman-Z score of -3.27. This is a bad value and indicates that LGVN is not financially healthy and even has some risk of bankruptcy.
LGVN has a Altman-Z score (-3.27) which is comparable to the rest of the industry.
There is no outstanding debt for LGVN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.27
ROIC/WACCN/A
WACC10.22%
LGVN Yearly LT Debt VS Equity VS FCFLGVN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

A Current Ratio of 7.60 indicates that LGVN has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 7.60, LGVN is in the better half of the industry, outperforming 72.36% of the companies in the same industry.
A Quick Ratio of 7.60 indicates that LGVN has no problem at all paying its short term obligations.
LGVN has a Quick ratio of 7.60. This is in the better half of the industry: LGVN outperforms 72.54% of its industry peers.
Industry RankSector Rank
Current Ratio 7.6
Quick Ratio 7.6
LGVN Yearly Current Assets VS Current LiabilitesLGVN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

5

3. Growth

3.1 Past

LGVN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.73%, which is quite impressive.
The Revenue has grown by 237.38% in the past year. This is a very strong growth!
Measured over the past years, LGVN shows a very negative growth in Revenue. The Revenue has been decreasing by -15.76% on average per year.
EPS 1Y (TTM)58.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.8%
Revenue 1Y (TTM)237.38%
Revenue growth 3Y22.35%
Revenue growth 5Y-15.76%
Sales Q2Q%857.14%

3.2 Future

The Earnings Per Share is expected to grow by 24.91% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 164.38% on average over the next years. This is a very strong growth
EPS Next Y70.14%
EPS Next 2Y29.78%
EPS Next 3Y24.91%
EPS Next 5YN/A
Revenue Next Year10.09%
Revenue Next 2Y14.53%
Revenue Next 3Y164.38%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LGVN Yearly Revenue VS EstimatesLGVN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M 40M
LGVN Yearly EPS VS EstimatesLGVN Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -2 -4 -6 -8 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LGVN. In the last year negative earnings were reported.
Also next year LGVN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LGVN Price Earnings VS Forward Price EarningsLGVN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LGVN Per share dataLGVN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as LGVN's earnings are expected to grow with 24.91% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.78%
EPS Next 3Y24.91%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LGVN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LONGEVERON INC-A

NASDAQ:LGVN (4/25/2025, 4:30:02 PM)

1.75

+0.12 (+7.36%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-28 2025-02-28/amc
Earnings (Next)05-09 2025-05-09/amc
Inst Owners8.72%
Inst Owner Change0%
Ins Owners10.02%
Ins Owner Change-0.36%
Market Cap26.13M
Analysts82.22
Price Target9.05 (417.14%)
Short Float %5.87%
Short Ratio2.65
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.41%
Min EPS beat(2)-23.99%
Max EPS beat(2)24.81%
EPS beat(4)2
Avg EPS beat(4)-21.03%
Min EPS beat(4)-106.22%
Max EPS beat(4)24.81%
EPS beat(8)2
Avg EPS beat(8)-16.61%
EPS beat(12)3
Avg EPS beat(12)-13.02%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)41.81%
Min Revenue beat(2)-7.27%
Max Revenue beat(2)90.89%
Revenue beat(4)2
Avg Revenue beat(4)328.54%
Min Revenue beat(4)-12.6%
Max Revenue beat(4)1243.14%
Revenue beat(8)2
Avg Revenue beat(8)145.18%
Revenue beat(12)5
Avg Revenue beat(12)107.88%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-718.75%
EPS NY rev (1m)5.92%
EPS NY rev (3m)5.92%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-5.12%
Revenue NY rev (1m)-19.64%
Revenue NY rev (3m)-23.01%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.92
P/FCF N/A
P/OCF N/A
P/B 1.19
P/tB 1.34
EV/EBITDA N/A
EPS(TTM)-4.21
EYN/A
EPS(NY)-1.26
Fwd EYN/A
FCF(TTM)-1
FCFYN/A
OCF(TTM)-0.93
OCFYN/A
SpS0.16
BVpS1.47
TBVpS1.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -96.33%
ROE -112.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 78.8%
FCFM N/A
ROA(3y)-116.31%
ROA(5y)-85.81%
ROE(3y)-177.95%
ROE(5y)-153.9%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.36%
GM growth 5Y20.42%
F-Score6
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 103.55%
Cap/Sales 41.47%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.6
Quick Ratio 7.6
Altman-Z -3.27
F-Score6
WACC10.22%
ROIC/WACCN/A
Cap/Depr(3y)90.92%
Cap/Depr(5y)89.88%
Cap/Sales(3y)69.8%
Cap/Sales(5y)62.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.8%
EPS Next Y70.14%
EPS Next 2Y29.78%
EPS Next 3Y24.91%
EPS Next 5YN/A
Revenue 1Y (TTM)237.38%
Revenue growth 3Y22.35%
Revenue growth 5Y-15.76%
Sales Q2Q%857.14%
Revenue Next Year10.09%
Revenue Next 2Y14.53%
Revenue Next 3Y164.38%
Revenue Next 5YN/A
EBIT growth 1Y21.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y24.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.02%
OCF growth 3YN/A
OCF growth 5YN/A